2nd Rare CNS and Neurodevelopmental Drug Development Summit

With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients' lives.

 

The 2nd Rare CNS and Neurodevelopmental Drug Development Summit is the definitive industry-dedicated forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.

 

Tightly focused on industry progress, join stakeholders exploring ASOs, gene therapies and small molecules across autistic syndromes and seizure phenotypes in at this unique drug sponsor conference.

 

Don't miss out on the industry's definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers, emerging therapeutic targets and translational biology

 

If you are working towards treatments for rare CNS and neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.

 

Group discounts and early booking rates are available. Please visit the website for full pricing information.

 

Time: 8:00 am - 3:50 pm

Email Share